Womack Family Group has a preference towards Life Sciences due to Mr. Womack’s substantial experience in organizing and investing in medical device companies.

ARTELLA Solutions, Inc.   www.artellainc.com
The company is an Independent Diagnostic Testing Facility (IDTF) that deploys wireless Mobile Cardiac Telemetry (MCT) patches that replaces a traditional, cumbersome Holter monitor with an unobtrusive, wearable patch that provides real-time monitoring of cardiac events and reports results under its proprietary back-end Reporting Engine. ARTELLA provides services to physicians, healthcare systems, and other IDTFs. Mr. Womack founded Artella and serves on the Board of Directors.

AMBROSE Cell Therapy   www.ambrosecelltherapy.com
The company was founded in 2018 by Matthew Feshbach to help people with chronic degenerative diseases, improve symptoms, function, and quality of life using adult stem cell therapy.

To accomplish this, AMBROSE accesses the mixed population of stem and regenerative cells in a patient’s fat (adipose tissue). This cell preparation, when clinical grade, is called adipose-derived stem and regenerative cells (ADRCs).

In 2019, the passage of the Right to Try Act dovetailed with the technologies, protocols, and patient criteria that Matt believed would best address the unmet need of no-option patients.

AMBROSE Cell Therapy procedures are performed by board-certified specialist physicians who provide cell therapy services at licensed, Joint Commission Accredited (JACO) facilities in Tampa, FL and Beverly Hills, CA. Mr. Womack was a founding investor in AMBROSE and serves on its Board of Directors.

SONOSTICS, Inc.   www.Sonostics.com
The company is based on MIT spin-off bio-engineering technology, and its laboratory data shows significant reversal of cognitive impairment by increasing cardiac output which nourishes the brain with more oxygen, nutrients and washes toxins. The company has developed the Heart Partner, an external device that rejuvenates the soleus muscles which in turn increases cardiac output with the resultant increase in brain blood flow and its benefits. Our managing Director, Bruce Badeau, is their strategic advisor assisting in the preparation and closing of a $20 million round and a $10 million round for store-front cognitive testing facilities.